Stimolare le staminali per curare
la sclerosi laterale amiotrofica
28 Maggio 2008 - CANADA
Secondo alcuni ricercatori potrebbe essere possibile curare la sclerosi laterale amiotrofica con una stimolazione del corpo attraverso le proprie cellule staminali.
28 Maggio 2008 - CANADA
Secondo alcuni ricercatori potrebbe essere possibile curare la sclerosi laterale amiotrofica con una stimolazione del corpo attraverso le proprie cellule staminali.
Il team, guidato dal neurologo Neil Cashman dell'universita' della British Columbia,
ha annunciato di avere trovato una "strada sicura, che attivi nei pazienti le cellule staminali del midollo osseo".Il progetto prevede lo sviluppo di "apparenti stimolanti che aumentino il numero delle cellule staminali nel corpo, nella speranza che si dirigano dove ci sono le lesioni delle cellule del sistema nervoso, rallentando la progressione della malattia". La ricerca e' gia' stata testata su otto pazienti, e ora sono previsti altri su piu' larga scala.
In Italia esiste già grazie a Mario Melazzini :
uno studio pilota sulla sicurezza del (CGS-F): come autostimolo a produrre cellule staminali
DA PUB-MED
Muscle Nerve. 2008 May;37(5):620-5.
Links
Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS).
Cashman N, Tan LY, Krieger C, Mädler B, Mackay A, Mackenzie I, Benny B, Nantel S, Fabros M, Shinobu L, Yousefi M, Eisen A.
ALS Centre Brain Research Centre, University of British Columbia, Vancouver, BC, Canada.
Amyotrophic lateral sclerosis (ALS) is characterized by degeneration of upper and lower motor neurons in the brain, brainstem, and spinal cord. It has been proposed that bone marrow (BM)-derived cells might supply motor neurons and other cells with a cellular milieu more conducive to survival in ALS. Direct injection of stem cells in ALS is problematic because of the large expanse of the neuraxis that would need to be injected. We reasoned that transiently increasing the number of circulating hematopoietic stem cells might be a useful therapeutic approach. However, agents stimulating the activation and mobilization of hematopoietic stem cells may have adverse effects such as activation of microglial cells. We conducted a small pilot trial of the collection and reinfusion of granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) in ALS patients and found no adverse effects, paving the way for a properly powered therapeutic trial with an optimized regimen of G-CSF.
PMID: 18335482 [PubMed - in process]
Links
Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS).
Cashman N, Tan LY, Krieger C, Mädler B, Mackay A, Mackenzie I, Benny B, Nantel S, Fabros M, Shinobu L, Yousefi M, Eisen A.
ALS Centre Brain Research Centre, University of British Columbia, Vancouver, BC, Canada.
Amyotrophic lateral sclerosis (ALS) is characterized by degeneration of upper and lower motor neurons in the brain, brainstem, and spinal cord. It has been proposed that bone marrow (BM)-derived cells might supply motor neurons and other cells with a cellular milieu more conducive to survival in ALS. Direct injection of stem cells in ALS is problematic because of the large expanse of the neuraxis that would need to be injected. We reasoned that transiently increasing the number of circulating hematopoietic stem cells might be a useful therapeutic approach. However, agents stimulating the activation and mobilization of hematopoietic stem cells may have adverse effects such as activation of microglial cells. We conducted a small pilot trial of the collection and reinfusion of granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) in ALS patients and found no adverse effects, paving the way for a properly powered therapeutic trial with an optimized regimen of G-CSF.
PMID: 18335482 [PubMed - in process]
Nessun commento:
Posta un commento